Merck Inc. known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of… read more.
UCB Canada Inc. is pleased to announce that Bimzelx (bimekizumab injection) has received authorization from Health Canada for two new indications. On February 23, 2024, BImzelx was approved… read more.
Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (Comirnaty Omicron XBB.1.5) for ages 6 months and older…. read more.
A new policy analysis, published in the journal Performance Enhancement & Health, highlights several gaps in current Canadian policy regulating muscle-building dietary supplements. Muscle-building dietary supplements, including whey protein, creatine… read more.
Health Canada has authorized the use of maralixibat oral solution (Livmarli) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), as recently announced by Mirum… read more.
SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs,… read more.
Heron Therapeutics, Inc., announced that Health Canada has issued a Notice of Compliance (NOC) to commercialize Zynrelef (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound… read more.
BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that Brukinsa (zanubrutinib) has… read more.
Bristol Myers Squibb Canada announced Health Canada has granted conditional approval (NOC/c) for Abecma (idecabtagene vicleucel; ide-cel) as the first and only B-cell maturation antigen (BCMA)-directed chimeric antigen… read more.
Health Canada issued a Notice of Compliance for Taltz (ixekizumab), from Eli Lilly, injection, 80 mg/mL, for the treatment of pediatric patients from six to less than 18… read more.
BeiGene, Ltd. a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
